Clinical Trial Update: A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC) [Phase 2]

View source ↗

Summary

This Phase 2 trial aims to evaluate adverse events and pharmacokinetics of Telisotuzumab Vedotin as a standalone therapy in adults with previously treated non-s…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• ABBV-399

Snippet

Sponsor: AbbVie | Conditions: Non-Small Cell Lung Cancer | Phase 2 | Status: RECRUITING